Transaction DateRecipientSharesTypePriceValue
21st December 2020Gillian C Ivers Read829Open or private sale$5.68$4,708.72
21st December 2020Gillian C Ivers Read1,875Exercise of derivative$0.00
21st December 2020Lindsey Rolfe1,728Open or private sale$5.68$9,815.04
21st December 2020Lindsey Rolfe3,438Exercise of derivative$0.00
15th December 2020Lindsey Rolfe14,153Payment by withholding$5.11$72,321.83
15th December 2020Lindsey Rolfe17,241Exercise of derivative$3.28$56,550.48
3rd December 2020Lindsey Rolfe625Exercise of derivative$0.00
3rd December 2020Lindsey Rolfe315Open or private sale$4.89$1,540.35
3rd December 2020Gillian C Ivers Read277Open or private sale$4.89$1,354.53
3rd December 2020Gillian C Ivers Read625Exercise of derivative$0.00
Clovis Oncology
Clovis Oncology logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Clovis Oncology, Inc. is a commercial stage biotechnology company. It engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets.

Ticker: CLVS
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1466301
Employees: 484
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $261 M (61%)
Inventory, Net: $27 M (0%)
Other Assets, Current: $15 M (0%)
Assets, Current: $323 M (-11%)
Property, Plant and Equipment, Net: $13 M (-12%)
Other Assets, Noncurrent: $22 M (-6%)
Assets: $628 M (-6%)
Accounts Payable, Current: $24 M (-24%)
Accrued Liabilities, Current: $38 M (0%)
Liabilities, Current: $113 M (-15%)
Liabilities: $726 M (-14%)
Common Stock, Value, Issued: $88 Th (60%)
Common Stock, Shares, Issued: $88 M (695%)
Additional Paid in Capital, Common Stock: $2 B (12%)
Retained Earnings (Accumulated Deficit): $2 B (8%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $45 M (0%)
Stockholders' Equity (Parent): $97 M (0%)
Liabilities and Equity: $628 M (-6%)
Revenue: $40 M (-51%)
Operating Income/Loss: $83 M (-49%)
Other Income, net: $10 M (-64%)
Provision for income taxes: $36 Th (-65%)